Citations

Clear

148 citation(s) found for "Stock, W".

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Duong, Vu H. , Ruppert, Amy S. , Borate, Uma , Stein, Eytan M. , Baer, Maria R. , Kovacsovics, Tibor , Blum, William , Arellano, Martha , Schiller, Gary J. , Olin, Rebecca L. , Foran, James M. , Litzow, Mark R. , Patel, Prapti A. , Redner, Robert L. , Al‐Mansour, Zeina , Swords, Ronan , Collins, Robert H. , Vergilio, Jo‐Anne, Heerema, Nyla A. , Rosenberg, Leonard, Yocum, Ashley O. , Marcus, Sonja, Druggan, Franchesca , Stefanos, Mona , Gana, Theophilus J. , Burd, Amy , Byrd, John C. , Levine, Ross L. , Boyiadzis, Michael , Byrd, John C. , Blum, William , Arellano, Martha L , Foran, James M , Lin, Tara L , Gana, Theophilus J , Duong, Vu H , Byrd, John C , Mims, Alice S , Stock, Wendy , Lin, Tara L. , Foster, Matthew C , Cogle, Christopher Ramin , Chen, Timothy Frank , Shoben, Abigail B. , Druker, Brian J

Mayo Clinic

Cancer | April 20, 2023 | Volume: 129 | Issue: 15 | Pages: 2308-2320

10.1002/cncr.34780 | PMID 37078412 Get It

AbstractBackgroundPatients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in this patient population.MethodsThis was a multicenter, open‐label, phase 2 substudy of the Beat AML Master Trial (ClinicalTrials.gov identifier NCT03013998) using a Simon two‐stage design. Eligible patients aged 60 years or older who had newly diagnosed AML with mutations in TP53 with or without a complex karyotype (cohort A; n = 45) or had a complex karyotype without TP53 mutation (cohort B; n = 13) received entospletinib 400 mg twice daily with decitabine 20 mg/m2 on days 1–10 every 28 days for up to three induction cycles, followed by up to 11 consolidation cycles, in which decitabine was reduced to days 1–5. Entospletinib maintenance was given for up to 2 years. The primary end point was complete remission (CR) and CR with hematologic improvement by up to six cycles of therapy.ResultsThe composite CR rates for cohorts A and B were 13.3% (95% confidence interval, 5.1%–26.8%) and 30.8% (95% confidence interval, 9.1%–61.4%), respectively. The median duration of response was 7.6 and 8.2 months, respectively, and the median overall survival was 6.5 and 11.5 months, respectively. The study was stopped because the futility boundary was crossed in both cohorts.ConclusionsThe combination of entospletinib and decitabine demonstrated activity and was acceptably tolerated in this patient population; however, the CR rates were low, and overall survival was short. Novel treatment strategies for older patients with TP53 mutations and complex karyotype remain an urgent need.
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
Bhatt, Vijaya Raj , Ulrich, Angela M. , Uy, Geoffrey L. , Stone, Richard M. , Stock, Wendy , Ojelabi, Michael Olayiwola , Yin, Jun , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Baer, Maria R. , Chow, Selina , Jatoi, Aminah , Ojelabi, Michael O , Klepin, Heidi D , Le-Rademacher, Jennifer G , Stock, Wendy , Bhatt, Vijaya Raj , Uy, Geoffrey , Klepin, Heidi D. , Le‐Rademacher, Jennifer

Mayo Clinic

JCO Oncology Practice | April 14, 2023 | Volume: 19 | Issue: 6 | Pages: e877-e891

10.1200/op.22.00822 | PMID 37058684 Get It

PURPOSE: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive chemotherapy trials at community versus academic cancer centers. METHODS: We used data from the Alliance for Clinical Trials in Oncology phase III trials that enrolled patients age ≥ 60 years with newly diagnosed AML between 1998 and 2002 in the Cancer and Leukemia Group B (CALGB) 9720 trial and between 2004 and 2006 in the CALGB 10201 trial. Centers funded by the NCI Community Oncology Research Program were identified as community cancer centers; others were designated as academic cancer centers. Logistic regression models and Cox proportional hazards models were used to compare 1-month mortality and overall survival (OS) by center type. RESULTS: Seventeen percent of the 1,170 patients were enrolled in clinical trials in community cancer centers. The study results demonstrated comparable rates of grade ≥3 adverse events (97% v 93%), 1-month mortality (19.1% v 16.1%), and OS (43.9% v 35.7% at 1 year) between community versus academic cancer centers, respectively. After adjusting for covariates, 1-month mortality (odds ratio, 1.40; 95% CI, 0.92 to 2.12; P = .11) and OS (hazard ratio, 1.04; 95% CI, 0.88 to 1.22; P = .67) were not statistically different among patients treated in community versus academic cancer centers. CONCLUSION: An older patient population, who have complex health care needs, can be successfully treated on intensive chemotherapy trials in select community cancer centers with outcomes comparable with that achieved at academic cancer centers.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
Sims, Matthew , Khanna, Sahil , Louie, Thomas , Kelly, Colleen , Hohmann, Elizabeth , Wang, Elaine E. L., Oneto, Caterina , Cohen, Stuart H. , Berenson, Charles S., Korman, Louis Y. , Lee, Christine , Lashner, Bret A., Kraft, Colleen S., Ramesh, Mayur , Silverman, Michael H. , Pardi, Darrell S. , Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Investigators, ECOSPOR IV, Hemaidan, Anmar, Kumar, Princy , Misra, Bharat , Nathan, Richard, Pullman, John, Williams, Jeffrey G., Acosta, Idalia, Odio, Alberto, Smith, Kent, Hansen, Val, Georgetson, Michael, Sheikh, Aasim , Arimie, Calin, Andrade, Gladys, O’Marro, Steven, Esfandyari, Tuba, Ritter, Timothy E., Baird, Ian Mcnicol, Colman, Ronald, Hernandez, Lilliam, Adams, Atoya, Walton, Marie, Arsenescu, Razvan, Shapiro, Max, Cook, Paul, Heuer, Marvin, Bogdanovich, Tatiana, Grimard, Doria, Butt, Debra, Gauthier, Stephanie , Guímont, Chantal, Kreines, Michael, Berman, Larry, Bennett, Michael , Fogel, Ronald, Gutierrez, Juan Carlos Moises, Pedersen, P.C. , Bressler, Adam, Nadar, Venkatesh, Newton, Eric, Abbas, Jalal, Jamal, Aamir, Benjamin, Sabrina, Ayub, Kamran, Oguchi, Godson, Pinero, Jose, Ramesh, Gowrappala, Sepe, Paul S., Brook, Loren, Ruthardt, Frederick, Surace, Lindsey, Hussain, Ayub, Rutland, Travis J., Schmalz, Micahel, Degala, Gourisankar, Phillips, Raymond E. , Stock, Kent, Bullock, Jeffrey, Onwueme, Kenolisa, Feuerstadt, Paul , Huang, Edward S. , Lee, Christine H. , Kraft, Colleen S. , Silverman, Michael, De, Ananya, Memisoglu, Asli, Lombardi, David A., Investigators, ECOSPOR IV, Nguyen, Hien , Tran, Huy, Smith, Kent, Weinstock, Leonard B. , Garcia‐Diaz, Julia , Colman, Ronald, Patel, Meenakshi, Shapiro, Max, Cook, Paul, Steiner, Theodore S. , Butt, Debra, Daley, Peter , Gauthier, Stephanie, Berman, Larry, Bennett, Michael, Pedersen, Peder, Newton, Eric, Diaz, Jorge, Abbas, Jalal, DuPont, Herbert L. , Jamal, Aamir, Talreja, Neetu, Ayub, Kamran, Phillips, Raymond

Mayo Clinic

JAMA Network Open | February 13, 2023 | Volume: 6 | Issue: 2 | Pages: e2255758

10.1001/jamanetworkopen.2022.55758 | PMID 36780159 Get It

ImportanceA safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence.ObjectivesTo evaluate the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks.Design, Setting, and ParticipantsThis phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US and Canadian outpatient sites from October 2017 to April 2022. Adults aged 18 years or older with recurrent CDI were enrolled in 2 cohorts: (1) rollover patients from the ECOSPOR III trial who had CDI recurrence diagnosed by toxin enzyme immunoassay (EIA) and (2) patients with at least 1 CDI recurrence (diagnosed by polymerase chain reaction [PCR] or toxin EIA), inclusive of their acute infection at study entry.InterventionsSER-109 given orally as 4 capsules daily for 3 days following symptom resolution after antibiotic treatment for CDI.Main Outcomes and MeasuresThe main outcomes were safety, measured as the rate of treatment-emergent adverse events (TEAEs) in all patients receiving any amount of SER-109, and cumulative rates of recurrent CDI (toxin-positive diarrhea requiring treatment) through week 24 in the intent-to-treat population.ResultsOf 351 patients screened, 263 were enrolled (180 [68.4%] female; mean [SD] age, 64.0 [15.7] years); 29 were in cohort 1 and 234 in cohort 2. Seventy-seven patients (29.3%) were enrolled with their first CDI recurrence. Overall, 141 patients (53.6%) had TEAEs, which were mostly mild to moderate and gastrointestinal. There were 8 deaths (3.0%) and 33 patients (12.5%) with serious TEAEs; none were considered treatment related by the investigators. Overall, 23 patients (8.7%; 95% CI, 5.6%-12.8%) had recurrent CDI at week 8 (4 of 29 [13.8%; 95% CI, 3.9%-31.7%] in cohort 1 and 19 of 234 [8.1%; 95% CI, 5.0%-12.4%] in cohort 2), and recurrent CDI rates remained low through 24 weeks (36 patients [13.7%; 95% CI, 9.8%-18.4%]). At week 8, recurrent CDI rates in patients with a first recurrence were similarly low (5 of 77 [6.5%; 95% CI, 2.1%-14.5%]) as in patients with 2 or more recurrences (18 of 186 [9.7%; 95% CI, 5.8%-14.9%]). Analyses by select baseline characteristics showed consistently low recurrent CDI rates in patients younger than 65 years vs 65 years or older (5 of 126 [4.0%; 95% CI, 1.3%-9.0%] vs 18 of 137 [13.1%; 95% CI, 8.0%-20.0%]) and patients enrolled based on positive PCR results (3 of 69 [4.3%; 95% CI, 0.9%-12.2%]) vs those with positive toxin EIA results (20 of 192 [10.4%; 95% CI, 6.5%-15.6%]).Conclusions and RelevanceIn this trial, oral SER-109 was well tolerated in a patient population with recurrent CDI and prevalent comorbidities. The rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.Trial RegistrationClinicalTrials.gov identifier: NCT03183141
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML
Johnson, Mary Ann , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Kovacsovics, Tibor , Olin, Rebecca L. , Blum, William , Schiller, Gary J. , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Borate, Uma , Byrd, John C. , Byrd, John C , Zeidner, Joshua F. , Foster, Matthew C , Johnson, Mary, Stock, Wendy , Madanat, Yazan F. , Lin, Tara L. , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9070-9073

10.1182/blood-2022-166715 Get It

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A P
Borate, Uma , Li, Rui , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Odenike, Olatoyosi , Patel, Prapti A. , Collins, Robert H. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Arellano, Martha , Blum, William , Schiller, Gary J. , Boyiadzis, Michael , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Gana, Theophilus J. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Byrd, John C. , Byrd, John C , Traer, Elie , Duong, Vu H. , Stock, Wendy , Madanat, Yazan F. , Smith, Catherine C. , Lin, Tara L. , Foster, Matthew C , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6200-6203

10.1182/blood-2022-167316 Get It

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
Aldoss, Ibrahim , Yin, Jun , Wall, Anna, Mrózek, Krzysztof , Liedtke, Michaela , Claxton, David F. , Appelbaum, Frederick R. , Erba, Harry P. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Luger, Selina M. , Erba, Harry Paul , Litzow, Mark R. , Larson, Richard A , Advani, Anjali S , Claxton, David F , Aldoss, Ibrahim , Foster, Matthew C , Larson, Richard A. , Advani, Anjali S. , Stock, Wendy

Mayo Clinic

Blood Advances | October 21, 2022 | Volume: 7 | Issue: 2 | Pages: 196-204

10.1182/bloodadvances.2022007791 | PMID 36269846 Get It

Abstract Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However, a similar correlation in adults is lacking. Here, we studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated on the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation (ED) (defined as <4 of 5 or 6 planned doses) on survival outcomes. The analysis included 176 patients who achieved complete remission and initiated the delayed intensification (DI) cycle. The median number of PEG-asparaginase doses administered before DI was 5 (range, 1-6), with 57 (32%) patients with ED. The ED patients were older (median, 26 vs 23 years; P = .023). Survival was apparently lower for ED patients compared with those receiving ≥4 doses, but this finding was not statistically significant (hazard ratio [HR], 1.82; 95% confidence interval [CI], 0.97-3.43; P = .06), with corresponding 5-year overall survival (OS) rates of 66% and 80%, respectively. In patients with standard-risk ALL, the ED of PEG-asparaginase adversely influenced OS (HR, 2.3; 95% CI, 1.02-5.22; P = .04) with a trend toward inferior event-free survival (EFS) (HR, 1.84; 95% CI, 0.92-3.67; P = .08). In contrast, there was no impact of early PEG-asparaginase discontinuation on OS (P = .64) or EFS (P = .32) in patients with high-risk disease based on the presence of high-risk cytogenetics, Ph-like genotype, and/or high white blood cell count at presentation. In conclusion, early PEG-asparaginase discontinuation is common in young adults with ALL and may adversely impact survival of patients with standard-risk ALL.
Artificial microRNA suppresses C9ORF72 variants and decreases toxic dipeptides in vivo
Cabrera, Gabriela Toro , Meijboom, Katharina E. , Abdallah, Abbas, Foster, Zachariah W. , Weiss, Alexandra , Wightman, Nicholas, Stock, Rachel , Gruntman, Alisha M. , Giampetruzzi, Anthony, Petrucelli, Leonard , Brown, Robert C., Mueller, Christian , Tran, Helen, Weiss, Alexandra, Gendron, Tania F. , Brown, Robert

Mayo Clinic

No container title available | September 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2081412/v1 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons, causing progressive muscle weakness and respiratory failure. The presence of an expanded hexanucleotide repeat in chromosome 9 open reading frame 72 (C9ORF72) accounts for most cases of familial ALS and frontotemporal dementia (FTD). To determine if suppressing expression of C9ORF72 gene products can reduce toxicity, we designed a set of artificial microRNAs (amiRNA) targeting the human C9ORF72 gene. Here we report that an AAV9-mediated amiRNA significantly suppresses expression of the C9ORF72 mRNA, protein, and toxic poly-dipeptides generated by the expanded repeat in the brain and spinal cord.